Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in InventoryChange in InventoryChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InflaRx (IFRX) Free Cash Flow (2016 - 2026)

InflaRx's Free Cash Flow history spans 9 years, with the latest figure at -$8.6 million for Q1 2026.

  • On a quarterly basis, Free Cash Flow rose 41.33% to -$8.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$33.4 million, a 34.77% increase, with the full-year FY2025 number at -$41.2 million, up 20.59% from a year prior.
  • Free Cash Flow hit -$8.6 million in Q1 2026 for InflaRx, down from -$5.7 million in the prior quarter.
  • Over the last five years, Free Cash Flow for IFRX hit a ceiling of $2027.4 in Q2 2022 and a floor of -$16.1 million in Q1 2024.
  • Historically, Free Cash Flow has averaged -$9.7 million across 5 years, with a median of -$10.6 million in 2024.
  • Biggest five-year swings in Free Cash Flow: tumbled 599012.69% in 2023 and later skyrocketed 55.1% in 2025.
  • Tracing IFRX's Free Cash Flow over 5 years: stood at -$5.2 million in 2022, then crashed by 128.74% to -$11.8 million in 2023, then dropped by 8.07% to -$12.8 million in 2024, then skyrocketed by 55.1% to -$5.7 million in 2025, then plummeted by 50.47% to -$8.6 million in 2026.
  • Business Quant data shows Free Cash Flow for IFRX at -$8.6 million in Q1 2026, -$5.7 million in Q4 2025, and -$10.5 million in Q3 2025.